SRSF2 and myelodysplastic syndrome: Current standard treatment for higher-risk MDS/AML has limited efficacy in patients with mutation of ASXL1 and/or SRSF2, which has led to these mutations being classified as adverse risk factors in the ELN 2022 recommendations [5].